Cognition Therapeutics
Clinical trials sponsored by Cognition Therapeutics, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a Synapse-Targeting drug slow Alzheimer's? Results expected May 2027 (estimated)
-
Could a Synapse-Targeting drug slow Alzheimer's?
Disease control OngoingThis Phase 2 trial tests an experimental drug called CT1812 in 540 people with early Alzheimer's disease. Participants receive either the drug or a placebo for 18 months. The goal is to see if CT1812 can slow declines in memory, thinking, and daily function. The study is active b…
Phase 2 • Sponsor: Cognition Therapeutics • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Experimental drug zervimesine made available to patients with lewy body dementia
Disease control Expanded access (ended)This expanded access program offers the experimental drug zervimesine (CT1812) to people aged 50 to 86 with mild-to-moderate dementia with Lewy bodies. Participants take one 100 mg pill daily for up to a year. The goal is to provide access to the drug and collect long-term safety…
Sponsor: Cognition Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC